The lack of a comprehensive analysis of TP53 mutations and their associated interaction networks across various cancer types hinders our ability to decipher the molecular intricacies underlying cancer progression and identify potential therapeutic vulnerabilities. This evidence concerns the gene TP53 and cancer.